ARYx Therapeutics, Inc.
ARYX · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Market Cap | $13,383 | $14,052 | $25,534 | $88,567 |
| - Cash | $2,954 | $1,404 | $6,297 | $7,409 |
| + Debt | $12,320 | $7,750 | $9,492 | $11,824 |
| Enterprise Value | $22,749 | $20,398 | $28,729 | $92,982 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,939 | -$3,011 | -$5,768 | -$5,060 |
| % Margin | – | – | – | – |
| Net Income | -$2,514 | -$3,636 | -$6,390 | -$5,787 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.075 | -0.11 | -0.22 | -0.21 |
| % Growth | 31.7% | 50% | -4.8% | – |
| Operating Cash Flow | -$4,046 | -$3,515 | -$6,423 | -$6,085 |
| Capital Expenditures | -$8 | $0 | $0 | -$44 |
| Free Cash Flow | -$4,054 | -$3,515 | -$6,423 | -$6,129 |